AstraZeneca admits rare blood clot risk with Covishield vaccine

Dr. Rajeev Jayadevan, a medical specialist, explained Thrombosis Thrombocytopenia Syndrome (TTS) as a rare occurrence of blood vessel clotting associated with specific vaccine usage.

Acknowledging that the Covid vaccines have helped in preventing numerous deaths, Jayadevan, who is the Co-Chairman of National Indian Medical Association (IMA) Covid Task Force in Kerala, stated that reports of such cases have also been highlighted in many reports.

Also Read: 2 linked to AAP, Congress arrested in Amit Shah fake video case

Rare Instances of Thrombosis Thrombocytopenia Syndrome (TTS)

“TTS is thrombosis with thrombocytopenia syndrome, which is basically clot in blood vessels of the brain or elsewhere, along with a low platelet count. It is known to occur in very rare instances following certain types of vaccines and also from other causes. According to the WHO, adenovirus vector vaccines in particular have been rarely associated with this condition,” he told ANI.”

Although Covid vaccines have prevented numerous deaths, reports of these extremely rare but potentially serious immune mediated events have also been published in reputed journals,” Dr Jayadevan added.

This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria “can, in very rare cases, cause TTS.”

According to several UK media reports, AstraZeneca has made the admission in court documents in connection with a case that alleges that the vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases.

Also Read: German Shepherd dog attacks 6-year-old girl in Ghaziabad society

Adverse Event Following Immunisation with Adenovirus Vector-Based Covid-19 Vaccines

The Serum Institute of India produced Covid-19 vaccine named Covishield but not using mRNA platform. It has been prepared using the viral vector platform. In the vaccine, a chimpanzee adenovirus – ChAdOx1 – has been modified to enable it to carry the Covid-19 spike protein into the cells of humans. This cold virus is basically incapable of infecting the receiver, but can very well teach the immune system to prepare a mechanism against such viruses.

Amid reports about clot in blood vessels in the UK media, the Serum Institute of India did not respond to the query.

Notably in 2023, the World Health Organisation (WHO) said in its report that TTS emerged as a new adverse event following immunisation in individuals vaccinated with Covid-19 non-replicant adenovirus vector-based vaccines.

Also Read: ओला कैब्स के सीईओ हेमंत बख्शी ने दिया इस्तीफा